Cardiovascular and renal outcomes of glucagon-like peptide 1 receptor agonists among patients with and without type 2 diabetes mellitus: A meta-analysis of randomized placebo-controlled trials

• DOI: 10.1016/j.ajpc.2024.100679
• Publication Date: 2024-05-07T15:58:32Z
• Authors: Frederick Berro R...; Linnaeus Louisse ...; John Vincent Maga...; Jade Monica Marie...; John Paul Aparece; Nathan Ross B. Ba...; Kyla Lara-Breitinger; Martha Gulati
• Keywords: Lixisenatide

Multiple cardiovascular outcomes trials (CVOTs) have shown the efficacy of GLP-1RAs in reducing major adverse events (MACEs) for high-risk patients. However, some CVOTs failed to demonstrate benefits.